PL375734A1 - Preparat do podawania drogą żołądkowo-jelitową zawierający ekstrat z zielonej herbaty i donor NO - Google Patents

Preparat do podawania drogą żołądkowo-jelitową zawierający ekstrat z zielonej herbaty i donor NO

Info

Publication number
PL375734A1
PL375734A1 PL03375734A PL37573403A PL375734A1 PL 375734 A1 PL375734 A1 PL 375734A1 PL 03375734 A PL03375734 A PL 03375734A PL 37573403 A PL37573403 A PL 37573403A PL 375734 A1 PL375734 A1 PL 375734A1
Authority
PL
Poland
Prior art keywords
formulation
donor
green tea
tea extract
containing green
Prior art date
Application number
PL03375734A
Other languages
English (en)
Other versions
PL212978B1 (pl
Inventor
Heinz Schneider
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of PL375734A1 publication Critical patent/PL375734A1/pl
Publication of PL212978B1 publication Critical patent/PL212978B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL375734A 2002-12-09 2003-11-13 Zastosowanie kompozycji zawierajacej ekstrakt z zielonej herbaty i donor tlenku azotu do wytwarzania preparatu do podawania droga zoladkowo-jelitowa PL212978B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10257360A DE10257360A1 (de) 2002-12-09 2002-12-09 Gastro-intestinal verabreichbare Formulierung und deren Verwendung

Publications (2)

Publication Number Publication Date
PL375734A1 true PL375734A1 (pl) 2005-12-12
PL212978B1 PL212978B1 (pl) 2012-12-31

Family

ID=32477462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL375734A PL212978B1 (pl) 2002-12-09 2003-11-13 Zastosowanie kompozycji zawierajacej ekstrakt z zielonej herbaty i donor tlenku azotu do wytwarzania preparatu do podawania droga zoladkowo-jelitowa

Country Status (23)

Country Link
US (1) US20060121125A1 (pl)
EP (1) EP1572175B1 (pl)
JP (1) JP2006510640A (pl)
KR (1) KR101031989B1 (pl)
CN (1) CN100367941C (pl)
AT (1) ATE345116T1 (pl)
AU (1) AU2003288047B2 (pl)
BR (1) BRPI0315075A8 (pl)
CA (1) CA2499006C (pl)
DE (2) DE10257360A1 (pl)
DK (1) DK1572175T3 (pl)
ES (1) ES2276136T3 (pl)
HR (1) HRP20050511B1 (pl)
IL (1) IL168854A (pl)
IS (1) IS2432B (pl)
MX (1) MXPA05006111A (pl)
NO (1) NO332734B1 (pl)
PL (1) PL212978B1 (pl)
PT (1) PT1572175E (pl)
RU (1) RU2314824C2 (pl)
TW (1) TWI349563B (pl)
WO (1) WO2004052352A1 (pl)
ZA (1) ZA200501924B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
WO2014150996A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Cancer treatment
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
CN112334205B (zh) * 2018-06-21 2022-09-06 Gs 加德士 天然物质提取用溶剂组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE502414C2 (sv) * 1990-05-28 1995-10-16 Ljungqvist Olle Medical Ab Användning av glukos för framställning av lösning för preoperativ administrering samt infusionslösning därför
GB9403935D0 (en) * 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
BR9607336A (pt) * 1995-02-23 1997-11-25 Novartis Nutrition Ag Composições de aminoácidos e utilidades das mesmas em nutrição clinica
GB9510037D0 (en) * 1995-05-18 1995-07-12 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JPH09227374A (ja) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd ストレスタンパク質産生抑制組成物
US6013273A (en) * 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
JPH10248538A (ja) * 1997-03-10 1998-09-22 Cheil Sugar Co Ltd α−波増進飲料用組成物及びこれを含有する飲料
EP0875155A1 (en) * 1997-05-01 1998-11-04 N.V. Nutricia Peri-operative drink
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
AU3760300A (en) * 1999-03-19 2000-10-09 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
EP1136073A1 (en) * 2000-03-22 2001-09-26 N.V. Nutricia Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress
WO2002001952A1 (fr) * 2000-07-05 2002-01-10 Hiromi Wada Fluide de preservation pour cellules et tissus
DE60011261T2 (de) * 2000-07-14 2005-08-25 Nutri-Fit Gmbh & Co. Kg Grüntee-Extrakt zur Behandlung von Cyclosporin oder Ascomycin induzierten Nieren-Funktionsstörungen
US6423349B1 (en) * 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery

Also Published As

Publication number Publication date
IS2432B (is) 2008-10-15
HK1087913A1 (zh) 2006-10-27
EP1572175B1 (de) 2006-11-15
AU2003288047A1 (en) 2004-06-30
HRP20050511A2 (en) 2005-10-31
CN100367941C (zh) 2008-02-13
CA2499006C (en) 2011-04-19
DE50305714D1 (de) 2006-12-28
RU2314824C2 (ru) 2008-01-20
ZA200501924B (en) 2005-11-30
NO20052978L (no) 2005-06-17
PT1572175E (pt) 2007-01-31
RU2005111766A (ru) 2005-09-10
BR0315075A (pt) 2005-08-16
JP2006510640A (ja) 2006-03-30
IL168854A (en) 2011-09-27
KR101031989B1 (ko) 2011-05-02
BRPI0315075A8 (pt) 2017-12-19
CA2499006A1 (en) 2004-06-24
DE10257360A1 (de) 2004-07-08
MXPA05006111A (es) 2005-08-16
WO2004052352A1 (de) 2004-06-24
CN1703210A (zh) 2005-11-30
HRP20050511B1 (en) 2008-01-31
IS7836A (is) 2005-05-03
NO20052978D0 (no) 2005-06-17
TW200418501A (en) 2004-10-01
NO332734B1 (no) 2012-12-27
EP1572175A1 (de) 2005-09-14
AU2003288047B2 (en) 2008-03-13
TWI349563B (en) 2011-10-01
US20060121125A1 (en) 2006-06-08
KR20050084207A (ko) 2005-08-26
ES2276136T3 (es) 2007-06-16
DK1572175T3 (da) 2007-03-19
PL212978B1 (pl) 2012-12-31
ATE345116T1 (de) 2006-12-15

Similar Documents

Publication Publication Date Title
MXPA03008045A (es) Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv.
WO2003049680A3 (en) Compositions containing both sedative and non-sedative antihistamines
AU2002257587A1 (en) Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
AU2002346296A1 (en) Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for the preparation of the same
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2005123032A3 (en) Haircare compositions and methods
AU2003221524A1 (en) Administration form for oral administration of active ingredients, vitamins and/or nutrients
MY137752A (en) Medicament for treating aseptic inflammations containing anemonin as effective component
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2006012213A3 (en) Composition and method for delivery of phytochemicals
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
HRP20050511A2 (en) Formulation, which can be administered gastrointestinally, containing green tea extract and an no donor
PT1485154E (pt) Dispositivo de inalação de pó
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
WO2004080414A3 (en) Composition and method for treating inflammations by reducing c-reactive protein
WO2005063757A3 (en) Novel crystalline forms of temozolomide
WO2001054676A3 (de) Formulierungen bei dehydratationszuständen
EP1707567A4 (en) NEW FUSED CYCLE COMPOUND
WO2005097153A3 (en) Extracts of passion fruit and uses thereof
WO2003059650A3 (de) Hülle einer score-karte
SI1572175T1 (sl) Formulacija iz ekstrakta zelenega caja in NO-donorja, ki se jo lahko daje gastrointestinalno
AU2002326191A1 (en) Pharmaceutical composition comprising an extract of elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
WO2002028398A1 (en) Compositions for treating diabetes